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Synchronous primary cancers are relatively uncommon in gen-
eral population.[1] Only 0.5-1.7% of  women with gynecological 
malignancies, have synchronous primary cancers of  the female 
genital tract.[2-6] Among them, the most common combination 
is synchronous primary endometrial and ovarian cancers.[2,3,5]
The pathogenesis of  synchronous primary endometrial and ovar-
ian cancers, remains unclear[5,7] The theory of  the secondary 
Müllerian system has been proposed to explain the development 
of  multiple primary cancers of  the female genital tract.[5-9] Ac-
cording to this theory, epithelia of  the female genital tract simul-
taneously respond to a carcinogenic stimulus.[7,8]
Perhaps those patients have a more fragile genome and prior ge-
netic damage may predispose to the development of  synchronous 
primary cancers of  the female genital tract.[7,10-14] Thus, em-
bryologic, hormonal or other phenomena may be associated with 
the development of  synchronous primary endometrial and ovar-
ian cancers.[5-10,12]
Systematic surgical staging is the treatment of  choice, for most 
patients with synchronous primary endometrial and ovarian can-
cers[2,3,5,15-21] More specifically, systematic surgical staging in 
those patients includes: total abdominal hysterectomy with bilat-
eral salpingo-oophorectomy, total omentectomy, appendectomy, 
pelvic and para-aortic lymphadenectomy, complete resection of  
all disease, biopsy of  any suspected lesion and pelvic washings.
[1,2,5,15-19,21-23]
It is obvious that systematic surgical staging allows a more clear 
decision for stage related postoperative adjuvant treatment.
[1,17,18] Appropriate surgical staging facilitates targeted therapy 
that minimize the morbidity of  overtreatment (radiation injury, 
chemotherapy toxicity), the effects of  undertreatment (recurrent 
disease, increased mortality) and maximize survival.[24]
Pelvic and para-aortic lymphadenectomy has diagnostic, thera-
peutic and prognostic value.[1,22,23] It defines accurately the 
extent of  disease and determines the prognosis of  patients.[1] 
Undoubtedly, it is necessary for the identification of  patients with 
stage III disease. [22,23] The extension of  pelvic and para-aortic 
lymphadenectomy (more than 14 lymph nodes) is an independent 
risk factor for postoperative complications.[17,18,25-27] Espe-
cially in elderly patients and in patients with relevant comorbidi-
ties (obesity, diabetes, coronary artery disease), morbidity must be 
carefully weighed against any survival advantage.[24,28,29]
The significance of  postoperative adjuvant treatment in patients 
with synchronous primary endometrial and ovarian cancers, re-
mains controversial and needs further investigation.[16,20,30] In 
most cases, postoperative adjuvant treatment should be individu-
alized according to the risk of  relapse of  each primary cancer.
[30,31] Moreover, the treatment of  one primary cancer does not 
compromise the treatment of  the other primary cancer.[32]
Especially in patients with unfavorable histologic types, high 
grade and/or advanced stage disease, required postoperative ad-
juvant treatment tailored to both tumors.[3,5,15,17-21,30,32-36] 
More specifically, postoperative adjuvant treatment in those pa-
tients includes: radiotherapy and/or chemotherapy.[1,21,30,36]
Postoperative adjuvant radiotherapy includes: external pelvic ra-
diotherapy and/or brachytherapy. It is the appropriate treatment 
for high risk primary endometrial cancer.[1,17,18]
Postoperative adjuvant chemotherapy is the appropriate treatment 
for advanced stage primary endometrial and ovarian cancers.[31] 
The most active chemotherapeutic agents for those patients, are: 
taxanes, anthracyclines and platinum compounds.[20,21]
Prognostic factors for synchronous primary endometrial and ovar-
ian cancers are: age, grade of  endometrial cancer, stage of  ovarian 
cancer and adjuvant treatment.[35,37,38] Patients with synchro-
nous primary endometrial and ovarian cancers have 5-year overall 
survival 85.9% and 10 year overall survival 80.3%.[16] However, 
patients with synchronous primary endometrial and ovarian can-
cers endometrioid type have a better overall survival compared 
with patients with non-endometrioid or mixed histologic types.
[39] Moreover, patients with synchronous primary endometrial 
and ovarian cancers have better overall survival compared with 
patients with single primary ovarian cancer.[30,32,35,39]
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The reason for the better overall survival of  patients with syn-
chronous primary endometrial and ovarian cancers, is not intui-
tively obvious.[16] Perhaps favorable prognosis related with the 
detection of  patients at early stage and low grade disease.[3,5,11-
13,15-34,40]
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